GSTM1 and cold agglutinin disease: Part A of the CADENZA study showed that 26 weeks of treatment with sutimlimab inhibited activity in the classical complement pathway, halted haemolysis, increased Hb levels, and reduced fatigue in patients with CAD, relative to placebo.11